br Statistical Analysis br GraphPad software San Diego
GraphPad 6 software (San Diego, CA, USA) was used for all data an-alyses. The difference between two independent datasets was analyzed by Student’s t test. The differen#
Supplemental Information can be found online at https://doi.org/10.
Z.L. developed the experiments, carried out the parameter estima-tions, and wrote the main part of the manuscript. Y.Z., H.C., and F.Z. took part in development of the mouse model. L.D. wrote parts of the manuscript and reviewed the manuscript. R.L. participated in coordination of the study and reviewed the manuscript. All authors read and approved the final manuscript.
CONFLICTS OF INTEREST
L.D. 3X FLAG an employee of Shanghai HyCharm Inc. A patent was filed for the methods of the immunogen design (application number
WO2014/183649A1). This does not alter the author’s adherence to all journal policies regarding sharing of data and materials.
This work was supported by the National Key Research and Develop-ment Program of China (2017YFC0909002) and the National Science and Technology Major Projects of China (Major Infectious Diseases 2017ZX10201301-003-004).
11. Rossille, D., Gressier, M., Damotte, D., Maucort-Boulch, D., Pangault, C., Semana, G., Le Gouill, S., Haioun, C., Tarte, K., Lamy, T., et al.; Groupe Ouest-Est des Leucémies et Autres Maladies du Sang; Groupe Ouest-Est des Leucémies et Autres Maladies du Sang (2014). High level of soluble programmed cell death ligand 1 in blood impacts overall survival in aggressive diffuse large B-Cell lymphoma: results from a French multicenter clinical trial. Leukemia 28, 2367–2375.
Molecular Therapy: Oncolytics
25. Ahmad, S.M., Svane, I.M., and Andersen, M.H. (2014). The stimulation of PD-L1-specific cytotoxic T lymphocytes can both directly and indirectly enhance antileu-kemic immunity. Blood Cancer J. 4, e230.
38. Holmström, M.O., Riley, C.H., Skov, V., Svane, I.M., Hasselbalch, H.C., and Andersen, M.H. (2018). Spontaneous T-cell responses against the immune check point programmed-death-ligand 1 (PD-L1) in patients with chronic myeloprolifera-tive neoplasms correlate with disease stage and clinical response. OncoImmunology 7, e1433521.
Contents lists available at ScienceDirect
journal homepage: www.elsevier.com/locate/biomaterials
A pH-responsive platform combining chemodynamic therapy with T
limotherapy for simultaneous bioimaging and synergistic cancer therapy
Jianmin Xiaoa,b,1, Guilong Zhangc,1, Rui Xue,1, Hui Chene, Huijuan Wangb, Geng Tianc, Bin Wangc, Chi Yangd, Guo Baid, Zhiyuan Zhangd, Hongyi Yangf, Kai Zhongf, Duohong Zoud,**, Zhengyan Wua,*
a Key Laboratory of High Magnetic Field and Ion Beam Physical Biology, Hefei Institutes of Physical Science, Chinese Academy of Sciences, Hefei, 230031, PR China
b Engineering and Materials Science Experiment Center, University of Science and Technology of China, Hefei, 230026, PR China
c Medicine and Pharmacy Research Center, Binzhou Medical University, Yantai, Shandong Province, 264003, PR China
d Department of Oral Surgery, Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, National Clinical Research Center for Oral Diseases, Shanghai Key Laboratory of Stomatology & Shanghai Research Institute of Stomatology, Shanghai, 200001, PR China
e Department of Dental Implant Center, Stomatologic Hospital & College, Anhui Medical University, Key Laboratory of Oral Diseases Research of Anhui Province, Hefei, 230032, PR China f High Magnetic Field Laboratory, Hefei Institutes of Physical Science, Chinese Academy of Sciences, Hefei, 230031, PR China